Ethicare GmbH
Quick facts
Phase 2 pipeline
- Enalapril Orodispersible Minitablet · Cardiovascular
Enalapril inhibits angiotensin-converting enzyme (ACE), reducing the production of angiotensin II and aldosterone, leading to vasodilation and decreased blood pressure.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: